<SEC-DOCUMENT>0001193125-23-253861.txt : 20231011
<SEC-HEADER>0001193125-23-253861.hdr.sgml : 20231011
<ACCEPTANCE-DATETIME>20231011073525
ACCESSION NUMBER:		0001193125-23-253861
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231011
FILED AS OF DATE:		20231011
DATE AS OF CHANGE:		20231011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		231319425

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d531066d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&nbsp;&#9745;&#8195;&#8195;&#8195;&#8195; Form
<FONT STYLE="white-space:nowrap">40-F&#8194;&nbsp;&#9744;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX and Nasdaq Trading Halt </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;11, 2023, Kazia Therapeutics Limited (the &#147;Company&#148;) announced that the Company has requested formal approval from the Australian Securities Exchange (ASX) to be removed from the official list of ASX pursuant to ASX Listing
Rule 17.11 (the &#147;Delisting&#148;). The Company expects that the Delisting will occur on Friday, 14&nbsp;November 2023. The Company&#146;s securities are expected to be suspended and cease to trade on the ASX at the close of trade on Friday,
10&nbsp;November 2023 (being two business days before the Delisting). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the announcement is furnished herewith as Exhibit 99.1 to
this report on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d531066dex991.htm">ASX Announcement of Kazia Therapeutics Limited dated October&nbsp;11, 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October&nbsp;11, 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d531066dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g531066g1011060824196.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX RELEASE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11
October 2023 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA ANNOUNCES VOLUNTARY DELISTING FROM ASX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 11 October 2023 </B>- Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) (<B>Kazia </B>or the <B>Company</B>), an
<FONT STYLE="white-space:nowrap">oncology-focused</FONT> drug development company, announces its intention to de-list from the Australian Securities Exchange (<B>ASX</B>). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delisting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia advises that it has submitted a formal
application to the ASX to be removed from the official list of the ASX (<B>Official List</B>) in accordance with ASX Listing Rule 17.11 (<B>Delist </B>or the <B>Delisting</B>). This formal request follows the receipt of <FONT
STYLE="white-space:nowrap">in-principle</FONT> advice from the ASX in relation to the proposed Delisting, subject to the satisfaction of the conditions set out below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has ultimately determined that the costs, administrative burden and commercial disadvantages of remaining listed on ASX outweigh any benefits of a
continued ASX listing. Following the Delisting, the Company will maintain its listing on the NASDAQ and the fully paid ordinary shares in the Company (<B>Shares</B>) will no longer be quoted on the ASX. Further details regarding the reasons for and
consequences of the Delisting are set out below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for seeking removal from the Official List </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board considers that it is in the best interests of the Company and its shareholders for the Company to Delist for the following reasons. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I><B><I>Costs</I></B><I>: The continued listing of Kazia on ASX requires it to incur considerable
corporate and administrative costs, including listing fees. Kazia is seeking to minimise its expenditure and would cease incurring such additional costs if it is removed from the official list of ASX. The Company considers the financial,
administrative and compliance obligations and costs associated with managing an ASX listing and a NASDAQ listing, including the higher level of regulatory compliance costs associated with a dual listing, noting that there are a number of material
differences between the NASDAQ listing rules and the ASX listing rules, unjustifiable and not in the best interests of the Company&#146;s securityholders. </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(b)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I><B><I>Access to larger equity markets with biotechnology focus</I></B><I>: The board of Kazia believes
that delisting from ASX whilst retaining the NASDAQ listing will enable Kazia to have access to a deeper market that better understands, and values, biotechnology businesses, thereby allowing it to more readily raise more capital on better terms,
from a wider investor base. This access is pivotal in assisting Kazia to raise appropriate growth capital to pursue its plans. </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(c)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I><B><I>Capital raisings</I></B><I>: The delisting from ASX and retention of a primary listing on NASDAQ
is expected to improve the Company&#146;s access to its institutional investor base and other financing options in the USA that currently has the most active biotechnology ecosystem on a global basis. Being dual listed on ASX and NASDAQ is currently
limiting fundraising options for Kazia. </I></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(d)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I></I><B><I>Location of directors and management</I></B><I>: With the exception of two non-executive
directors, the Company&#146;s remaining non-executive board member, Karen Krumeich, the Company&#146;s Chief Financial Officer and Dr John Friend, the Company&#146;s CEO, Managing Director and Interim Chairman, are now based in the USA, reflecting
the Company&#146;s focus on international rather than domestic markets. </I></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrangements for sale of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will notify shareholders whose securities are held on the Company&#146;s Australian principal share register of the time and date at which the
Company will be removed from the Official List shortly and inform those shareholders that if they wish to sell their securities on ASX they will need to do so before that date and if they don&#146;t do so, they will only be able to sell their
securities on-market on NASDAQ. The Company will also inform those shareholders generally what they will need to do if they wish to sell their securities on NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No change will occur to the quotation and trading of the Company&#146;s securities on NASDAQ because of the removal from the Official List. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consequences for the Company and its shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consequences for the Company and its shareholders if the Company is removed from the Official List of the ASX are set out below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>shareholders will no longer be able to trade their Shares on the ASX; </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(b)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>the Company&#146;s Shares will only be capable of being traded on NASDAQ in the form of ADSs, which will
require shareholders to transfer their Shares to ADSs to trade on NASDAQ and engage a suitably qualified Australian broker or a US based broker who is able to trade on NASDAQ, or by off-market, private transactions, which will require shareholders
to identify and agree terms with potential purchasers of Shares; </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(c)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>following Delisting, the Company will not be subject to the ASX Listing Rules. In particular, the following
ASX Listing Rule requirements will no longer apply: </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(i)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>continuous disclosure and other periodic reporting requirements (although the Company&#146;s reporting
requirements (including continuous disclosure &#150; see below) will still be governed by the Corporations Act 2001 (Cth) (Corporations Act), the applicable rules of NASDAQ and its reporting obligations under US securities laws, as described in
section (e)&nbsp;below); </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(ii)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>disclosure of certain information under the ASX Listing Rules (including changes of capital or information
related to directors and the auditor of the Company); </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(iii)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>restrictions on the issue of new capital (such as the inability of the Company to issue in excess of 15% of
its capital in any 12-month period without shareholder approval) and certain restrictions on transactions with related parties (although these will still be governed by the Corporations Act and the applicable rules of NASDAQ);
</I></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(iv)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>requirements relating to significant changes to the Company&#146;s activities; and
</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(v)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>the requirement to report against the ASX Corporate Governance Principles and Recommendations;
</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(d)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>if, following removal from the Official List, the Company has 100 or more shareholders, it will be an
&#147;unlisted disclosing entity&#148; under the Corporations Act. </I></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>As an unlisted disclosing entity, the Company
will still be required to give continuous disclosure of material matters in accordance with the Corporations Act by filing notices with ASIC under section 675 of the Corporations Act and the Company will still be required to lodge annual audited and
half-yearly financial statements in accordance with the requirements of the Corporations Act. However, if the Company ceases to be an unlisted disclosing entity there will be no ongoing requirement for the Company to give continuous disclosure of
material matters under section 675, or lodge half-yearly financial statements reviewed by an auditor, but as a public company it will continue to be required to lodge annual audited financial statements. In addition, the Company notes that it will
also be required to fulfill its public reporting obligations under US securities laws as a US public company and, while its securities are listed on NASDAQ, its disclosure obligations under applicable NASDAQ listing rules; </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(e)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>the related party transaction provisions of the Corporations Act will continue to apply to the Company as an
Australian public company; and </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(f)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>directors will continue to be subject to directors&#146; duties under the Corporations Act, including to act
in good faith and in the best interests of the Company. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some shareholders may consider that the reduction of obligations associated
with an ASX listing is a disadvantage, including minority shareholders. While there will be differences in the regulatory regimes before and after the Delisting, minority shareholders will continue to benefit from the protections in the Corporations
Act, such as in relation to the alteration of shareholder rights, financial reporting obligations and holding annual meetings of shareholders. Shareholders will also have protections because of US securities laws and applicable NASDAQ listing rules.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX&#146;s <FONT
STYLE="white-space:nowrap">in-principle</FONT> decision to approve the Delisting is subject to the Company&#146;s compliance with the following conditions imposed by ASX under Listing Rule 17.11 and Guidance Note 33: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(a)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Company sends written or electronic communications to all shareholders whose Shares are held on the
Company&#146;s Australian principal share register, in form and substance satisfactory to ASX (</I><B><I>Notice</I></B><I>), setting out: </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(i)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>the nominated time and date at which the entity will be removed from the ASX and that:
</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(A)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>if they wish to sell their Shares on ASX, they will need to do so before then; and
</I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(B)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>if they don&#146;t, thereafter they will only be able to sell the underlying securities on-market on NASDAQ
in the form of ADSs; and </I></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(ii)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>generally what they need to do if they wish to sell their securities on NASDAQ. </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(b)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The removal shall not take place any earlier than one month after the date the information in the Notice has
been sent to shareholders.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>(c)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Company releases the full terms of this decision to the market upon making a formal application to ASX
to remove the Company from the official list of ASX.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Importantly, Kazia shareholder approval is not required for the Delisting.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrangements to enable shareholders to sell their Shares or convert them to ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to the Delisting, the Company has established a voluntary ADS conversion facility pursuant to which shareholders may elect to convert their Shares
to ADSs. The company will bear the fees associated with the ADS conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia will release additional documents that provide more information about
the Delisting Facilities, including information and any relevant forms for shareholders in connection with the Delisting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Remedies available to
shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a shareholder of the Company considers the removal from the Official List to be contrary to the interests of the shareholders of the
Company as a whole or oppressive to, unfairly prejudicial to, or unfairly discriminatory against a shareholder or shareholders, it may apply to the court for an order under Part 2F.1 of the Corporations Act. Under section 233 of the Corporations
Act, the court can make any order that it considers appropriate in relation to the Company, including an order that the Company be wound up or an order regulating the conduct of the Company&#146;s affairs in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a shareholder of the Company considers that the removal form the Official List involves &#147;unacceptable circumstances&#148;, it may apply to the
Takeovers Panel for a declaration of unacceptable circumstances and other orders under Part 6.10 Division 2 Subdivision B of the Corporations Act (refer also to Guidance Note 1: Unacceptable Circumstances issued by the Takeovers Panel). Under
section 657D of the Corporations Act, if the Takeovers Panel has declared circumstances to be unacceptable, it may make any order that it thinks appropriate to protect the rights or interests of any person or group of persons, where the Takeovers
Panel is satisfied that those rights or interests are being affected, or will be or are likely to be affected, by the circumstances. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Timetable </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proposed timetable for the satisfaction of conditions and the expected date of removal of the Company from the Official List are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Event</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Indicative&nbsp;Date*</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notification of intention to delist</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">11&nbsp;October&nbsp;2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Despatch of letters and ADS Conversion Facility election forms to shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">12 October 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date: Participation in ADS Conversion Facility</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10&nbsp;November&nbsp;2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Last day for trading of the Company&#146;s Shares on ASX</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10 November 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Completion of removal of the Company from the Official List of the ASX</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">14 November 2023</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dates and times are indicative only and subject to change by the Company or ASX. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares may continue to be traded on ASX up until the last trading day, after which trading will be suspended until the Delisting on the next trading day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inquiries: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Matters Pty Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>cosec@companymatters.com.au</U> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an <FONT STYLE="white-space:nowrap">oncology-focused</FONT> drug
development company, based in Sydney, Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which
isbeing developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase II study in glioblastoma reported promising signals of
clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of
these havingreported encouraging interim data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, andFast
Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also awarded (FTD) in July 2023 for the treatment of solid tumour brain metastases harbouring PI3K pathway mutations in combination with radiation therapy. In
addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data
has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A Phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit
<U>w</U><U>w</U><U>w</U><U>.</U><U>k</U><U>aziat</U><U>h</U><U>e</U><U>r</U><U>a</U><U>p</U><U>e</U><U>u</U><U>ti</U><U>cs</U><U>.</U><U>c</U><U>o</U><U>m</U> or follow us on Twitter @KaziaTx. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject
to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product
development, related to regulatory approvals, related to Kazia&#146;s executive leadership changes, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual
Report, filed on form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g531066g1011060824196.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g531066g1011060824196.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X Q8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM=4L669[5?M,+ISOC(^8?ES_ ,!KP.B$KH<XV844451 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
